Hybrigenics hires head of corporate and business development

William Vickery joins firm from ExonHit

Hybrigenics, a French bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialised in protein interactions services, has appointed William Vickery to the newly created position of head of corporate and business development.

Vickery was for five years senior director of business development at ExonHit.

Prior to joining ExonHit Therapeutics in 2006 and since 2003, he was business development director of Roche Pharmaceuticals in the US, where he was responsible for out-licensing and divestiture of Roche-developed assets.

‘I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases,’ said Vickery.

You may also like